Avidity Biosciences Reports Fourth Quarter 2024 Financial Results and Recent Highlights

Building on success across its three clinical programs, Avidity is leading in rare neuromuscular diseases with a strong balance sheet to execute on a transformational 2025 Major milestones anticipated for each rare neuromuscular program in 2025, including preparing for Avidity's first BLA submission Commercial preparations well underway in anticipation of three potential successive product launches for DMD, DM1 and FSHD starting in 2026Phase 1/2 EXPLORE44® top-line del-zota data to be presented at the 2025 ...